Just a moment, the page is loading...


Published Proposals

Access to clinical trial data provides opportunities to conduct further research that can help advance medical science or improve patient care. This helps ensure the data provided by research participants are used to maximum effect in the creation of knowledge and understanding.

Proposal Number Sponsor/Funder Title Lead researcher Affiliation Publication(s)
631 GSK Predictors of BPH Progression Dr. Stephen Freedland, MD Duke UniversityDurham, North CarolinaUSA https://cancerpreventionresearch.aacrjournals.org/content/early/2017/04/27/1940-6207.CAPR-17-0019




647 GSK Assessing and Reporting Heterogeneity of Treatment Effect in Randomized Clinical Trials David M. Kent, MD, MSc Institute for Clinical Research and Health Policy Studies, Tufts Medical CentBoston, MAUSA Kent DM, Nelson J, Dahabreh IJ, Rothwell PM, Altman DG, Hayward RA. Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials. Int J Epidemiol. 2016 Jul 3. pii: dyw118. [Epub ahead of print] PMID: 27375287

651 GSK Descriptive evaluation of SAE reporting rates in vaccine clinical trials among Latin American children. Thomas Verstraeten P95 Pharmacovigilance and Epidemiology ServicesLeuven, BE Baay M, Bollaerts K, Struchiner C, Verstraeten T. Background rates of disease in Latin American children from a rotavirus vaccine study. Hum Vaccin Immunother. 2017 Apr 25:1-5. doi: 10.1080/21645515.2017.1320007. PMID: 28441094


669 GSK A multi-center, double-blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression - efficacy and adverse outcomes. Jon Jureidini University of Adelaide Le Noury J, Nardo JM, Healy D, et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 2015;351:h4320.


674 GSK Antiepileptic drug monotherapy for epilepsy: an overview of systematic reviews andnetwork meta-analysis Antony Marson University of Liverpool https://doi.org/10.1136/bmj.j1390

911 GSK Outcome Measures in Systemic Lupus Erythematosus: Constructing a Meaningful Response Index from Existing Clinical Trial Data Lindsy Forbess, MD, MSc Cedars-Sinai Medical CenterLos Angeles, CAUS Failure of a systemic lupus erythematosus response index developed from clinical trial data: lessons examined and learned. Forbess LJ, Bresee C, Wallace DJ, Weisman MH. Lupus. 2017 Jan 1:961203317692433. doi: 10.1177/0961203317692433. [Epub ahead of print] PMID: 28173737


930 GSK MASTERMIND: Stratification of glycaemic response the ADOPT and RECORD studies Professor Andrew Hattersley, M.D. FRS University of Exeter Medical SchoolExeter, UK John M. Dennis, William E. Henley, Michael N. Weedon, Mike Lonergan, Lauren R. Rodgers, Angus G. Jones, William T. Hamilton, Naveed Sattar, Salim Janmohamed, Rury R. Holman, Ewan R. Pearson, Beverley M. Shields, Andrew T. Hattersley
Diabetes Care Sep 2018, 41 (9) 1844-1853; DOI: 10.2337/dc18-0344

Rodgers LR, Dennis JM, Shields BM, et al. Prior event rate ratio adjustment produced estimates consistent with randomized trial: a diabetes case study. J Clin Epidemiol. 2020;122:78-86. doi:10.1016/j.jclinepi.2020.03.007

Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol. 2019;7(6):442-451.

Donnelly LA, Dennis JM, Coleman RL, et al. Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study [published online ahead of print, 2020 Aug 14]. Diabetes Care. 2020;dc201104. doi:10.2337/dc20-1104

945 ViiV THE CD4/CD8 RATIO AS A PREDICTOR OF NON-AIDS EVENTS DURING ANTIRRETROVIRAL THERAPY: CONFIRMATION OF ITS PREDICTIVE VALUE AND IMPACT OF MARAVIROC IN TREATMENT-EXPERIENCED PATIENTS Santiago Moreno University Hospital Ramón y CajalMadrid, Spain Serrano-Villar S, Caruana G, Zlotnik A, Pérez-Molina JA, Moreno S. Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals. Antimicrobial Agents and Chemotherapy. 2017; 61(12). doi: 10.1128/AAC.01763-17.PMID: 28993335.

946 GSK Assessing models for changes in tumour size over time and how they relate to survival times. Raluca Eftimie Division of Mathematics, University of DundeeDundee, UK Mistry, H.B., Orrell, D. & Eftimie, R. Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma. Cancer Chemother Pharmacol 81, 325-332 (2018).

977 GSK The implication of central adjudication of COPD exacerbations by experts for treatment effect estimates and sample size calculation Milo Puhan University of ZurichZurich, CH Bias away from the null due to miscounted outcomes? A case study on the TORCH trial
Stefanie Muff, Milo A Puhan, Leonhard Held
January 1, 2017

993 GSK A Spirometric Z-Score Based Reappraisal of the TORCH Study(GSK-SCO30003): Salmeterol and Fluticasone Propionate in COPD. Carlos A. Vaz Fragoso, MD Yale University School of Medicine https://www.tandfonline.com/doi/abs/10.1080/15412555.2018.1424815
998 GSK Determination of minimally important difference for short form 36 and Facit Fatigue for Systemic lupus erythematosus Meenakshi Jolly, MD, MSCP Rush University Medical CenterChicago, ILUSA Devilliers H, Annapureddy N, Jolly M. Minimal Clinically Important Differences for Generic Patient Reported Outcomes Tools in SLE [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

1000 GSK Review of fever and febrile convulsion rates in children after trivalent influenza vaccine. Dr Jean Li-Kim-Moy, MBBS, FRACP National Centre for Immunisation Research and SurveillanceThe Children's Hospital at WestmeadSydney, AU Li-Kim-Moy, Jean, Wood, Nicholas, Jones, Cheryl, Macartney, Kristine, and Booy, Robert. (2018), Impact of fever and antipyretic use on influenza vaccine immune responses in children. 10.1097/INF.0000000000001949


1016 GSK Statistical methods for estimating the duration of protection of malaria vaccines: secondary analysis of data from the RTSS/AS02A trial in Mozambique. Paul Milligan London School of Hygiene and Tropical MedicineLondon, UK https://doi.org/10.1016/j.vaccine.2020.05.086
Yin Bun Cheung, Xiangmei Ma, K.F. Lam, Paul Milligan,
Estimation of the primary, secondary and composite effects of malaria vaccines using data on multiple clinical malaria episodes,
Vaccine, Volume 38, Issue 32, 2020, p. 4964-4969
1028 ViiV Impact of dolutegravir on CD4+/CD8+ ratio and CD4+ percentage in HIV-infected naive patients. José Ramón Blanco Hospital San Pedro - Center for Biomedical Research of La Rioja (CIBIR), SPAIN https://doi.org/10.1016/j.cmi.2017.11.016
1058 ViiV Ritonavir-boosted protease inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimens: a systematic review and individual patient data me Alvaro H Borges Centre for Health & Infectious Diseases ResearchRigshospitalet, University of CopenhagenCHIP, Department of Infectious Diseases and Rheumatology,Section 2100, FinsencentretBlegdamsvej 9DK-2100 Copenhagen ØDenmark https://doi.org/10.1093/cid/ciw236
1078 Lilly Nocebo effects in the treatment of bipolar disorder: Results from an individual study participant level meta-analysis of the placebo arm of olanzapine clinical trials Seetal Dodd Barwon Health Dodd S, Walker AJ, Brnabic AJM, Hong N, Burns A, Berk M. Incidence and characteristics of the nocebo response from meta-analyses of the placebo arms of clinical trials of olanzapine for bipolar disorder.
Bipolar Disord. 2018;00:1-9. https://doi.org/10.1111/bdi.12662

1079 ViiV The effects of maraviroc versus efavirenz in combination with zidovudine/abacavir on the CD4/CD8 ratio in treatment-naïve HIV-infected individuals. Sergio Serrano-Villar, MD PhD Deparment of Infectious DiseasesUniversity Hospital Ramón y CajalMadrid, Spain. Serrano-Villar S, Caruana G, Zlotnik A, Pérez-Molina JA, Moreno S. Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals. Antimicrobial Agents and Chemotherapy. 2017; 61(12). doi: 10.1128/AAC.01763-17.PMID: 28993335.


1084 GSK Studies on the relationship between corticosteroids and unfavorable medical effects. A study based on the BLISS-52 and BLISS-76 clinical trials. Ronald van Vollenhoven, MD, PhD Karolinska InstituteDepartment of MedicineStockholm, Sweden "Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial."


1088 GSK A study to identify risk factors that modify Rotarix efficacy and influence the time to rotavirus gastroenteritis among vaccinated and unvaccinated African infants. Joann Gruber University of North Carolina at Chapel Hill Gruber JF, Becker-Dreps S, Hudgens MG, Brookhart MA, Thomas JC, Jonsson Funk
M. Timing and predictors of severe rotavirus gastroenteritis among
unvaccinated infants in low- and middle-income countries. Epidemiol Infect


Gruber JF, Becker-Dreps S, Hudgens MG, Brookhart MA, Thomas JC, Jonsson Funk
M. Timing of Rotavirus Vaccine Doses and Severe Rotavirus Gastroenteritis
among Vaccinated Infants in Low- and Middle-Income Countries. Epidemiology


1090 GSK Validating the test-negative case-control design for estimating rotavirus vaccine effectiveness using gold-standard randomized controlled trial data from South Africa and Malawi (Rota-037) M. Elizabeth Halloran Fred Hutchinson Cancer Research Center; Department of Biostatistics, University of Washington http://dx.doi.org/10.1016/j.vaccine.2016.10.077
1100 Boehringer Ingelheim Systolic blood pressure level and risk of intracerebral hemorrhage. Jacoba P Greving Julius Center for Health Sciences and Primary Care UMC Utrecht http://www.neurology.org/content/88/2/177.full.html
1103 GSK A study on the possible association between antidepressant response to SSRIs and proneness for side effects Elias Eriksson, MD, PhD University of GothenburgGothenburg, Sweden https://doi.org/10.1038/mp.2017.147
1136 Takeda Can Machine Learning Algorithms using General Labs Predict Clinical Remission and Mucosal Healing for Patients on Vedolizumab? Peter Higgins University of Michigan https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.14510
1137 GSK Immunotherapy trial simulators: Using mathematical, computational and statistical techniques to simulate trial design for new products in the treatment, vaccination and immunoprophylaxis of disease. Roy Anderson, PhD Imperial College LondonLondonUK Cite this article: Hadjichrysanthou C, Caue¨t E,
Lawrence E, Vegvari C, de Wolf F, Anderson
RM. 2016 Understanding the within-host
dynamics of influenza A virus: from theory
to clinical implications. J. R. Soc. Interface 13:
1140 Boehringer Ingelheim Evaluation of the effect of incidental beta blocker use on clinical response to the EGFR TKI, afatinib John Heymach, MD, PhD MD Anderson Cancer Center https://clinicalstudydatarequest.com/Approved-Requests-DataSharingAgreement-Published.aspx
1141 GSK Multivariate methods for meta-analysis of vaccine studies with multiple correlated outcomes Merryn Voysey Nuffield Department of Primary Care Health Sciences, University of Oxford http://jamanetwork.com/journals/jamapediatrics/fullarticle/2627571
1148 Lilly Meta-analysis of the risk of relapse in bipolar disorder Dr. Joaquim Radua FIDMAG Germanes Hospitalàries & King’s College London Radua et al. Meta-analysis of the risk of subsequent mood episodes in bipolar disorder. Psychotherapy and Psychosomatics, in Press. DOI: 10.1159/000449417
1154 GSK Developing New Outcome Measures for SLE by Deconvoluting Available Datasets Peter E. Lipsky, MD Lupus Research InstituteNew York, NYUSA https://onlinelibrary.wiley.com/doi/full/10.1002/art.40522
1173 GSK, Lilly Initial severity and antidepressant efficacy for anxiety disorders: an individual patient data meta-analysis Ymkje Anna de Vries Interdisciplinary Center Psychopathology and Emotion regulation, Department of Psychiatry, University Medical Center Groningen, the Netherlands https://doi.org/10.1002/da.22737
1206 GSK Efficacy of Belimumab on Mucocutaneous Involvement in Patients with Systemic Lupus Erythematosus (MUCOBEL) Kuhn, Annegret Interdisciplinary Center of Clinical Trials (IZKS), University Clinic of Mainz, Germany
1257 GSK An independent evaluation of the cardiovascular risk of rosiglitazone: meta-analysis of GSK’s publicly available clinical trial data Joseph S. Ross, MD, MHS Yale University School of MedicineYale-New Haven Hospital Center for Outcomes Research and Evaluation https://doi.org/10.1136/bmj.l7078
1292 Lilly Applications of Item Response Theory to Clinical ADHD Research: Analysis of the ADHDRS-IV and Modeling Response to Treatments and Item-Level Treatment Sensitivity Alex Sturm University of California, Los Angeles Sturm, A., McCracken, J. T., & Cai, L. (2017). Evaluating the Hierarchical Structure of ADHD Symptoms and Invariance Across Age and Gender. Assessment. 2017 Jun 1:1073191117714559. doi: 10.1177/1073191117714559.
1320 GSK Utility of a measure of Lupus Low Disease Activity State in SLE Pei Xuan Ong (Emily) Monash Health https://ard.bmj.com/content/early/2019/01/24/annrheumdis-2018-214427
1323 Lilly Detection of uninformative clinics during the trial of a new drug using statistical and machine learning techniques Praveen Deorani KKT Technology pte. Ltd. Craig, Kevin & Liman, Christian & Yan, Yang & Goyal, Shubham & Roy, Nawal. (2017). More of what works: Detection of informative sites during the conduct of clinical trials using machine learning.

1331 Boehringer Ingelheim Impact of baseline diabetes and obesity statuses on outcomes post-ischemic stroke Colleen Bauza Medical University of South Carolina in Public Health Sciences Bauza, Colleen; Martin, Renee; Yeatts, Sharon D.; Borg, K; Magwood, Gayenell; Selassie, Anbesaw; and Ford, Marvella E. (2018) Determining the joint effect of obesity and diabetes on all-cause mortality and cardiovascular-related mortality following an ischemic stroke.

Bauza, Colleen; Martin, Renee; Yeatts, Sharon D.; Borg, K; Magwood, Gayenell; Selassie, Anbesaw; and Ford, Marvella E. (2018) Determining the joint effect of obesity and diabetes on functional disability at 3-months and on all-cause mortality at 1-year following an ischemic stroke.

1374 GSK A novel representation of vaccine efficacy trial datasets for use in computer simulation of vaccination policy Michael M. Wagner University of Pittsburgh Tajgardoon M, Wagner MM, VisweswaraS, Zimmerman RK. A Novel Representation of Vaccine Efficacy Trial Datasets for use in Computer Simulation of Vaccination Policy. AMIA Summits on Translational Science Proceedings. 2018;2017:389.


1403 ViiV Mathematical modeling of the HIV transmission risk during the first 24 weeks after initiation of antiretroviral therapy in naïve HIV-infected MSM Juan Berenguer Hospital General Universitario Gregorio Marañón Abstract can be found here, presented at 9th IAS Conference on HIV Science, July 2017, Paris, France:


see page 502, abstract # WEPEC0967:
"HIV transmission from condomless anal intercourse differs by initial ART regimen in HIV-infected MSM"
1430 GSK Comparison of various remission criteria for SLE. A study based on the BLISS-52 and BLISS-76 clinical trials. Ronald van Vollenhoven Department of Medicine, Solna Parodis I#, Emamikia S#, Gomez A, Gentline C, Arkema EV, Chatzidionysiou K, van Vollenhoven RF. Evaluation of Definitions Of Remission In Systemic Lupus Erythematosus (DORIS): a post-hoc analysis of two randomised clinical trials. The Lancet Rheumatology. 2019 Sep; [Accepted; In production] #Contributed equally
1455 Boehringer Ingelheim Prediction of major bleeding in atrial fibrillation patients with a history of stroke or transient ischemic attack Jacoba Greving Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands http://stroke.ahajournals.org/content/early/2017/09/20/STROKEAHA.117.019183/tab-article-info
1456 ViiV Impact of ongoing side effects on the efficacy of initial antiretroviral therapy Andrew Carr St Vincent's Hospital, Sydney http://www.croiconference.org/sessions/fda-snapshot-algorithm-may-overestimate-efficacy-initial-art
1457 Lilly Initial severity and efficacy of antipsychotics for schizophrenia and bipolar mania: Individual participant level analyses of placebo-controlled studies. Stefan Leucht Department of Psychiatry and Psychotherapy TU-München https://www.ncbi.nlm.nih.gov/pubmed/28939419
1470 Takeda, UCB The efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease Shomron Ben-Horin M.D. Gastroenterology Department, First Affiliated Hospital of Sun-YatSen University, Guangzhou, China Ben-Horin S, Zhao Y, Guo J, Mao R, Novack L, Sergienko R, Zhang J, Kobayashi T, Hibi T, Chowers Y, Colombel JF, Peyrin-Biroulet L, Kaplan G, Chen MH. Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials. BMJ Open. 2019 Jan 25;9(1):e024222
1473 Roche Comparison of the pharmacokinetics of oral once-monthly 150mg ibandronate between ethnic Europeans and Taiwan post-menopausal osteoporotic women across two phase 1 studies Keh-Sung Tsai (1) Department of Laboratory Medicine, National Taiwan University Hospital(2) Institute of Epidemiology and Preventive Medicine, National Taiwan University https://link.springer.com/article/10.1007%2Fs00198-019-05127-y
1475 Boehringer Ingelheim Predicting safety and efficacy of afatinib treatment of NSCLC Assoc/Prof Michael Sorich Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, Australia Cancers 2018, 10, 384; doi:10.3390/cancers10100384
1528 GSK A Swapping Method for Average Treatment Effect Estimation Bimal Sinha Statistics, the University of Maryland at Baltimore County (UMBC) https://www.tci-thaijo.org/index.php/thaistat/article/view/163194/117937
1569 GSK Melancholic symptoms in bipolar depression and response to lamotrigine Dr. Evyn Peters Department of Psychiatry, University of Saskatchewan (U of S), Saskatchewan, Canada Peters, E. M., Bowen, R., & Balbuena, L. (2018). Melancholic Symptoms in Bipolar II Depression and Responsiveness to Lamotrigine in an Exploratory Pilot Study. Journal of clinical psychopharmacology.
DOI: 10.1097/JCP.0000000000000947


1575 GSK, Lilly Early improvement in individual symptoms and response to antidepressants in patients with major depressive disorder Ymkje Anna de Vries Interdisciplinary Center Psychopathology and Emotion regulation, University Center of Psychiatry, University Medical Center Groningen, the Netherlands https://doi.org/10.1192/bjp.2018.122
1593 GSK JANUVIA/JANUMET HTA Submission(Germany) Dr. Rainer Woker MSD Sharp & Dohme GmbH https://www.g-ba.de/informationen/nutzenbewertung/398/
1595 Boehringer Ingelheim A Novel Approach to Developing Comprehensive Profile of Adverse Event (AE) Data from Clinical Trials Sharayu Paranjpe Cytel Statistical Software and Services Pvt. Ltd Sharayu Paranjpe & Anil Gore. Adversity Index for Clinical Trials: An Inclusive Approach for Analysis of Safety Data. https://arxiv.org/abs/1806.00204
1599 Roche Predictors of exposure, adverse and therapeutic effects of BRAF/MEK inhibitors in advanced melanoma. Michael Sorich Flinders University https://www.ncbi.nlm.nih.gov/pubmed/30758912
1622 ViiV A systematic literature review and Individual patient-level data enhanced network meta-analysis to determine the comparative efficacy and safety of first-line HIV antiretroviral therapies Steve Kanters School of Population and Public Health Kanters, S. (2019). Comparative efficacy and safety of first-line treatments for HIV patients for clinical guideline development and the impact of individual patient data. University of British Columbia.

doi 10.14288/1.0383244
1624 Lilly A Meta-analysis of Tardive Dyskinesia Rates in Studies Comparing Second Generation Antipsychotics (SGAs) with each other or to First-Generation Antipsychotics (FGAs). Christoph U Correll The Zucker Hillside Hospital Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first-and second-generation antipsychotics in comparative randomized controlled trials:
a meta-analysis. World Psychiatry. 2018 Oct;17(3):330-340. doi:
10.1002/wps.20579. PubMed PMID: 30192088; PubMed Central PMCID: PMC6127753.
1626 GSK Factors associated with Prostate Cancer in Prostate Needle Biopsy Daniel M. Moreira University of Illinois at Chicago https://doi.org/10.1016/j.juro.2018.06.018
1629 GSK Assessing sex-differences and the effect of timing of vaccination on immunogenicity, reactogenicity and efficacy of vaccines in young children Merryn Voysey University of Oxford https://doi.org/10.1016/j.vaccine.2017.09.002
1630 GSK A framework for individualized prediction of the rate and severity of asthma exacerbations Mohsen Sadatsafavi Faculty of Pharmaceutical Sciences and Faculty of Medicine, University of British Columbia https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A7412
1633 ViiV Comparative effect of dolutegravir and raltegravir on CD4+/CD8+ ratio, CD4%, and multiple T-cell marker recovery. SPRING-2 study. Jose Ramon Blanco Hospital San Pedro - Center for Biomedical Research of La Rioja (CIBIR), SPAIN Blanco JR, Alejos B, Moreno S. Immune recovery markers in a double blind clinical trial comparing dolutegravir and raltegravir based regimens as initial therapy (SPRING-2). PLoS One. 2020 Jan 16;15(1):e0226724.
1640 GSK Effect of Fluticasone/Salmeterol on Chronic Bronchitis Symptoms and Associated Patient Reported Outcomes: a post-hoc analysis of the TORCH trial Victor Kim Lewis Katz School of Medicine, Temple University. https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A7727
1692 Boehringer Ingelheim, GSK Predictors of chronic obstructive pulmonary disease progression Akihiro Hisaka Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba university, Chiba, Japan Kawamatsu, S.; Jin, R.; Araki, S.; Yoshioka, H.; Sato, H.; Sato, Y.; Hisaka, A. Scores of Health-Related Quality of Life Questionnaire Worsen Consistently in Patients of COPD: Estimating Disease Progression over 30 Years by SReFT with Individual Data Collected in SUMMIT Trial. J. Clin. Med. 2020, 9, 2676 https://doi.org/10.3390/jcm9082676
1695 GSK Outcome measures and baseline predictors of response to belimumab treatment. Ioannis Parodis Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden Ioannis Parodis, Sharzad Emamikia, Alvaro Gomez, Iva Gunnarsson, Ronald F. van Vollenhoven & Katerina Chatzidionysiou
(2018): Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies, Expert Opinion on Biological Therapy,




Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus. Hernández-Breijo B, Gomez A, Soukka S, Johansson P, Parodis I.
Autoimmun Rev. 2019 Aug 10:102372. doi:


1731 GSK Host characteristics impacting Rotarix immunogenicity and correlates of protection for rotavirus gastroenteritis, a multi-site pooled analysis of individual-level clinical trial data Julia M. Baker Department of Epidemiology, Rollins School of Public Health, Emory University http://ars.samrc.ac.za/ARS%202019/ARS%20posters/Baker%20Oral%20polio%20vaccine%20interferes%20.pdf

1732 Astellas, Boehringer Ingelheim, GSK, Lilly, Novartis, Roche, Sanofi, Takeda, UCB Assessing heterogeneity in relative treatment efficacy by age, sex and comorbidity. Dr David A McAllister University of Glasgow https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1427-1#article-info

Hanlon, P., Hannigan, L., Rodriguez-Perez, J. et al. Representation of people with comorbidity and multimorbidity in clinical trials of novel drug therapies: an individual-level participant data analysis. BMC Med 17, 201 (2019)

DOI: 10.1186/s12916-019-1427-1
1741 Lilly Predictors of exposure, therapeutic and adverse effects of drugs used in the treatment of advanced breast cancer and advanced colorectal cancer. Dr Ashley Mark Hopkins Flinders University https://www.frontiersin.org/articles/10.3389/fonc.2019.00789/full
Lim, H.H., Hopkins, A.M., Rowland, A. et al. Targ Oncol (2019) 14: 743. https://doi.org/10.1007/s11523-019-00683-z
1779 GSK Evaluation of the effect of inhaled corticosteroids (ICS) on blood eosinophil count (EOS) in patients with COPD Professor Jørgen Vestbo DMSc FRCP FERS Division of Infection, Immunity and Respiratory MedicineUniversity of Manchester, UK https://erj.ersjournals.com/content/52/suppl_62/OA2125
1907 GSK Critical characterization of the impact of clinical-pathological tumoral features on recurrence risk dynamics of NSCLS. Tommaso De Pas European institute of Oncology , Milan https://doi.org/10.1016/j.ejca.2019.11.005
2084 GSK Relationship between plasma levels of a1-Antitrypsin levels and the severity of airflow limitation Marc Miravitlles Pneumology Department. Hospital Universitari Vall d'Hebron. Barcelona, Spain https://www.archbronconeumol.org/en-serum-levels-alpha1-antitrypsin-their-relationship-articulo-S1579212920300100

DOI: 10.1016/j.arbres.2019.03.001

5453 Roche Evaluation of Postmastectomy Radiotherapy in Women with HER-2 positive Breast Cancer Youssef Zeidan American University of Beirut, Medical Center Abi Jaoude J, de Azambuja E, Makki M, et al. Post-Mastectomy Radiation Therapy in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Patients: Analysis of the HERA Trial. Int J Radiat Oncol Biol Phys. 2020;106(3):503-510. doi:10.1016/j.ijrobp.2019.10.022
5459 GSK Placebo Effects in Asthma Randomized Clinical Trials: Their Magnitudes, Causes and Potential for Improving Care Shawn D. Aaron The Ottawa Hospital Research Institute, University of Ottawa https://www.atsjournals.org/doi/full/10.1513/AnnalsATS.201901-071OC
5642 GSK FEV1 decline across BMI gradient in COPD patients who were part of large randomized controlled trial over at least 3 years. Don D Sin Centre for Heart Lung Innovation, St Paul's Hospital and Division of Respiratory Medicine, University of British Columbia,Vancouver, BC V6Z 1Y6, Canada Sun, Y., Milne, S., Jaw, J.E. et al. BMI is associated with FEV1 decline in chronic obstructive pulmonary disease: a meta-analysis of clinical trials. Respir Res 20, 236 (2019). https://doi.org/10.1186/s12931-019-1209-5